| Target Price | $26.00 |
| Price | $1.98 |
| Potential | |
| Number of Estimates | 3 |
| 3 Analysts have issued a price target Bioline RX Ltd Sponsored ADR 2027 . The average Bioline RX Ltd Sponsored ADR target price is $26.00. This is higher than the current stock price. The highest price target is , the lowest is . | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Bioline RX Ltd Sponsored ADR stock has an average upside potential 2027 of . |
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | ??? | ??? |
| ??? | ??? | |
| Net Margin | ??? | ??? |
| ??? | ??? |
2 Analysts have issued a sales forecast Bioline RX Ltd Sponsored ADR 2026 . The average Bioline RX Ltd Sponsored ADR sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | ??? | ??? |
| ??? | ??? | |
| EV/Sales | ??? |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| Analyst Rating | Date |
|---|---|
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


